Spyre Therapeutics (SYRE) Draws Bullish Targets Amid Volatile Trading
Spyre Therapeutics (SYRE) is experiencing volatile trading despite positive clinical trial results for its SPY002 drug in ulcerative colitis, leading analysts to raise price targets. Insider stock sales, however, caused a temporary selloff. The company maintains a strong cash position and pipeline, indicating a tug-of-war between long-term bullish sentiment and short-term trading reactions to insider activity.
Will Spyre’s US$500 Million ATM and Russell Exit Change Spyre Therapeutics' (SYRE) Narrative
Spyre Therapeutics recently filed a US$500 million at-the-market equity offering and an omnibus shelf registration, while also being removed from several Russell Value indexes. This article explores how these developments, particularly the large equity program, will impact Spyre's investment narrative and potential implications for investors. The company's valuation is considered high for a loss-making, pre-revenue business, raising concerns about further dilution to fund its pipeline.
Spyre Therapeutics CEO Cameron Turtle sells $1.32m in shares
Spyre Therapeutics CEO Cameron Turtle sold 15,000 shares of the company's common stock for approximately $1.32 million on July 1, 2026, as part of a Rule 10b5-1 trading plan. These sales occurred after a significant 450% stock return over the past year, with the stock trading at $86.63 and having a market cap of $7.51 billion. Despite the sale and an InvestingPro analysis indicating the stock is overvalued, Mr. Turtle still directly holds 582,540 shares, and other recent news highlights positive phase 2 trial results and increased price targets from Deutsche Bank and Stifel.
Spyre Therapeutics (NASDAQ:SYRE) CFO Scott Burrows sells $658k in shares
Spyre Therapeutics CFO Scott Burrows sold 7,500 shares of the company's common stock for over $658,000 on July 1, 2026, following the exercise of stock options. The sales were executed under a Rule 10b5-1 trading plan and involved shares sold at weighted average prices between $87.55 and $88.37. This transaction comes after the company's shares surged 450% in the past year, with the stock currently trading above its InvestingPro Fair Value, indicating potential overvaluation.
Spyre Therapeutics (SYRE) CFO exercises options, sells 7,500 shares under 10b5-1 plan
Spyre Therapeutics' CFO, Scott L. Burrows, exercised stock options for 7,500 shares at $14.50 and subsequently sold these shares in the open market at weighted average prices of $87.55 and $88.37. These transactions were executed on July 1, 2026, under a pre-arranged Rule 10b5-1 trading plan established on November 10, 2025. Post-transaction, Burrows retains significant equity in the company, including 97,994 common shares directly, 67,476 restricted stock units, and 352,357 remaining option shares.
[Form 4] Spyre Therapeutics, Inc. Insider Trading Activity
Sheldon Sloan, Chief Medical Officer at Spyre Therapeutics, Inc., exercised options for 8,334 shares of common stock at $27.46 per share and subsequently sold them on July 1, 2026, at weighted average prices of $87.52 and $88.34. These transactions were executed under a Rule 10b5-1 trading plan adopted in June 2025. Following the sales, Sloan holds no directly owned common shares but retains 305,000 outstanding stock options, part of a larger grant scheduled to vest over four years.
Spyre Therapeutics Announces Grants of Inducement Awards
Spyre Therapeutics, Inc. announced the grant of inducement awards to six non-executive employees, including stock options to purchase 58,843 shares and 2,134 restricted stock units (RSUs). These awards were approved by the independent Compensation Committee of the Board of Directors on July 1, 2026, and are material to the employees' acceptance of employment, aligning with Nasdaq Listing Rule 5635(c)(4). The stock options have a 10-year term and an exercise price of $88.89, with vesting periods detailed for both options and RSUs.
Spyre Therapeutics Announces Grants of Inducement Awards
Spyre Therapeutics, Inc. announced the grant of inducement awards to six non-executive employees. These awards include stock options to purchase 58,843 shares and 2,134 restricted stock units (RSUs), approved on July 1, 2026, and deemed material to the employees' acceptance of employment. The stock options have a 10-year term and an exercise price of $88.89, with vesting schedules tied to continuous service.
Form 144 SPYRE THERAPEUTICS INC For: 1 July By Investing.com
This article consists solely of a short announcement that SPYRE THERAPEUTICS INC filed a Form 144 for July 1st. It provides no further details regarding the content of the filing or its implications. The content is primarily a header and repeated small text mentions of the filing.
SYRE (NASDAQ) Form 144: Insider sales and 45,000-share notice
Spyre Therapeutics (SYRE) submitted a Form 144 notice for the proposed sale of 45,000 shares of Common Stock, linked to options exercised in June 2023. The filing also detailed two Rule 10b5-1 transactions by Cameron W. Turtle in May and June 2026, each for 15,000 shares, totaling over $2 million. As of July 1, 2026, 86,841,253 shares were outstanding.
Spyre Therapeutics: Deep And Diverse Immunology Pipeline Awaiting Data (NASDAQ:SYRE)
Spyre Therapeutics is a clinical-stage immunology company developing long-acting antibody therapies for inflammatory bowel disease (IBD) and rheumatology. The company has a well-funded balance sheet, allowing it to advance its Phase 2 assets, SPY001 and SPY002, which have shown encouraging Part A data. The author rates SYRE a speculative "Buy" due to its valuation already pricing in positive developments and the lack of current product revenue, awaiting placebo-controlled and combination therapy data.
Spyre Therapeutics Stock Outlook Hinges on 2026 Study Catalysts
Spyre Therapeutics is a clinical-stage biotech company focusing on inflammatory bowel disease (IBD) with a diverse pipeline of long-acting antibodies. The company's stock outlook for 2026 is heavily dependent on the clinical proof-of-concept data from its six upcoming Phase II study readouts. While its "multiple shots on goal" strategy offers potential, the company faces significant execution risks, including clinical trial failures, cash burn, and intense competition in the IBD market.
Is SYRE Stock a Buy Now or a Wait-and-See Biotech Story Today
Spyre Therapeutics (SYRE) presents a dilemma for investors: while its pipeline is advancing and it boasts a large cash balance, the stock has already seen significant gains without commercial product revenue. Its high valuation reflects future clinical success that is yet to be proven, making it a "wait-and-see" scenario rather than a clear "buy now" opportunity, especially given intense competition in the IBD market.
Spyre Therapeutics Insider Sold Shares Worth $1,307,000, According to a Recent SEC Filing
A recent SEC filing revealed that an insider at Spyre Therapeutics sold shares valued at $1,307,000. This transaction could be a routine part of an insider's financial planning or may indicate a change in their outlook on the company's stock. Investors often monitor insider transactions for insights into a company's financial health and future prospects.
Spyre Therapeutics CFO Burrows sells $1.3m in SYRE stock
Spyre Therapeutics CFO Scott L Burrows sold 15,000 shares of SYRE stock for approximately $1.3 million after exercising stock options. These transactions occurred on June 25, 2026, following a significant 477% surge in the company's stock over the past year. Despite the sales, Burrows still directly holds 97,994 shares, including restricted stock units set to vest in future installments.
Enterprise value to EBIT forward of Spyre Therapeutics, Inc. – NASDAQ:SYRE
The article discusses the enterprise value to EBIT forward of Spyre Therapeutics, Inc. (NASDAQ: SYRE). It provides a brief overview of the company's financial data as listed on the Nasdaq Stock Market. The content is presented from TradingView, focusing on financial metrics for the pharmaceutical company.
Form 4 Spyre Therapeutics Inc For: 26 June By Investing.com
This article from Investing.com reports on a Form 4 filing by Spyre Therapeutics Inc. for June 26. The brevity of the article indicates it is a factual notice rather than an in-depth analysis. It includes the stock symbol SYRE and notes a -0.88% change, alongside various other market data.
Spyre Therapeutics, Inc Actuals & Estimates (NASDAQ:SYRE)
This article provides an overview of Spyre Therapeutics, Inc. (NASDAQ:SYRE) stock, including its current price, market capitalization, and historical performance. It also details analyst forecasts, financial actuals and estimates, upcoming earnings dates, and general company information. The stock has shown significant growth over the last year, with analysts predicting further potential.
Spyre Therapeutics CFO Burrows sells $1.3m in SYRE stock By Investing.com
Spyre Therapeutics CFO Scott L Burrows sold 15,000 shares of SYRE stock for approximately $1.3 million, after exercising stock options for the same number of shares. The company's stock has seen a significant 477% surge over the past year, though InvestingPro analysis indicates it may be overvalued. Burrows now directly holds 97,994 shares, including restricted stock units.
Spyre Therapeutics (SYRE) CFO sells 15,000 shares after option exercise
Spyre Therapeutics' CFO, Scott L. Burrows, engaged in an exercise-and-sale transaction, acquiring 15,000 shares through stock options at $14.50 and subsequently selling them on the open market at weighted average prices around $87.12-$87.14. This transaction generated approximately $1.31 million while leaving him with a direct holding of 97,994 common shares, including RSUs, and a substantial portion of unexercised stock options. The event is characterized as a routine equity and compensation management move.
Form 4 Spyre Therapeutics Inc For: 26 June By Investing.com
This article briefly reports on a "Form 4" filing for Spyre Therapeutics Inc. related to June 26. These filings typically disclose changes in beneficial ownership of a company's securities by insiders. The article provides no specific details beyond the filing's date and the company involved.
Enterprise value to EBIT forward of Spyre Therapeutics, Inc. – BOATS:SYRE
This article provides the enterprise value to EBIT forward for Spyre Therapeutics, Inc. (SYRE). It appears to be a financial data point from TradingView, which aggregates market, reference, and SEC filing data from various providers.
Spyre Therapeutics (NASDAQ: SYRE) launches $500M at‑the‑market program
Spyre Therapeutics has initiated an "at-the-market" (ATM) program, filing a Form S-3ASR to offer up to $500 million in common stock through a sales agreement with TD Cowen. This program allows the company to sell shares periodically, with proceeds intended for advancing its IBD and RD programs, funding preclinical studies, clinical trials, manufacturing, and general corporate purposes. The filing also carries forward $36.55 million in unsold securities from a previous registration.
Enterprise value to EBITDA forward of Spyre Therapeutics, Inc. – NASDAQ:SYRE
This article focuses on the enterprise value to EBITDA forward for Spyre Therapeutics, Inc. (NASDAQ: SYRE). It provides financial data and market information related to the company, indicating its status within the pharmaceuticals and health technology sectors. The content primarily appears to be a financial data snippet from a larger platform rather than an analytical article.
What's Going On With Spyre Therapeutics Stock On Wednesday?
Spyre Therapeutics (NASDAQ: SYRE) stock plunged over 12% on Wednesday due to significant insider stock sales, despite being up more than 160% year-to-date and 450% over the past year. The sales, totaling approximately $399.7 million from Fairmount Healthcare Fund II L.P. and a separate transaction from director Michael Thomas Henderson, occurred after the company reported positive Phase 2 SKYLINE trial data for SPY002 and SPY001 in ulcerative colitis, leading to a $463.5 million public offering. Technically, the stock exhibits a strong bullish trend with positive moving averages and MACD, though the RSI is in neutral territory.
Enterprise value to revenue forward of Spyre Therapeutics, Inc. – NASDAQ:SYRE
This article provides financial data for Spyre Therapeutics, Inc. (NASDAQ:SYRE), specifically focusing on its enterprise value to revenue forward metric. The content appears to be a financial data snippet from TradingView, indicating no trading activity during market close.
Price to earnings forward of Spyre Therapeutics, Inc. – BOATS:SYRE
This article provides a financial data point for Spyre Therapeutics, Inc. (SYRE), focusing on its forward price-to-earnings ratio. The content indicates that the specific value for this metric is not available or "No trades" information is currently displayed. The piece is hosted on TradingView, a financial charting and analysis platform.
SYRE (NASDAQ): Affiliate files Form 144 to sell 15,000 shares on 06/25/2026
A Form 144 notice has been filed for Spyre Therapeutics (SYRE), indicating an affiliate plans to sell 15,000 shares of common stock on June 25, 2026, stemming from a stock option exercise. The filing also details three prior sales by Scott Burrows totaling 27,500 shares between April and June 2026. This administrative filing highlights ongoing insider activity related to equity compensation and prior stock dispositions.
Form 4 Spyre Therapeutics Inc For: 23 June By Investing.com
This article from Investing.com reports on a Form 4 filing for Spyre Therapeutics Inc. related to activities on June 23. It notes that the stock symbol SYRE saw a 3.85% increase. The piece is primarily a brief announcement accompanied by various financial market data and related news not directly pertaining to the Form 4 filing itself.
Director Michael Henderson Sells 20,000 Shares of Spyre Therapeu
Michael Henderson, a Director at Spyre Therapeutics Inc (SYRE), sold 20,000 shares of the company on June 22, 2026. Following this transaction, Henderson now owns 68,606 shares. Over the past year, Henderson has sold a total of 100,000 shares, with no insider purchases, and the stock was trading at $100 per share at the time of the recent sale.
Spyre Therapeutics director-affiliated fund sells $399.7m stock
Fairmount Healthcare Fund II L.P., an investment fund affiliated with a director of Spyre Therapeutics (NASDAQ:SYRE), sold 4,684,781 shares of the company's common stock for approximately $399.7 million on June 23, 2026. The sale occurred after the conversion of Series B Preferred Stock into common stock, following which the fund holds no common stock from this transaction, but retains convertible Series A Preferred Stock. Despite the sale, Spyre's stock has since gained 13.8%, trading near its 52-week high, while analysts have raised price targets following positive drug trial results and a recent public offering.
Spyre Therapeutics director Henderson sells $2 million in stock
Spyre Therapeutics director Michael Thomas Henderson sold 20,000 shares of company stock for $2 million at $100 per share, through a pre-arranged trading plan. This sale occurred while the stock was near its 52-week high after a significant 530% return over the past year. InvestingPro analysis suggests the stock is currently overvalued, despite recent positive phase 2 trial results for SPY002 and a successful $463.5 million stock offering.
Spyre (SYRE) fund converts Series B preferred, then exits common stake
Fairmount Healthcare Fund II L.P., associated with Fairmount Funds Management LLC, converted 16,667 shares of Spyre Therapeutics' Series B Preferred Stock into 666,680 shares of Common Stock. Immediately following this conversion, the fund sold 4,684,781 shares of Common Stock at $85.31 per share, liquidating its direct common stock holdings. Fairmount retains indirect exposure through Series A Preferred Stock convertible into 13,841,800 common shares.
Form 4 Spyre Therapeutics Inc For: 23 June By Investing.com
This article reports on a Form 4 filing for Spyre Therapeutics Inc, indicating a regulatory disclosure for the company on June 23. Form 4s detail changes in beneficial ownership of company stock by insiders, such as officers, directors, and major shareholders. The article is brief and does not include specific details of the filing but points to its publication on Investing.com.
Director at Spyre Therapeutics (SYRE) sells 20,000 shares under 10b5-1 plan
Michael Thomas Henderson, a director at Spyre Therapeutics (SYRE), sold 20,000 shares of common stock at $100.00 per share on June 22, 2026, totaling $2 million. This transaction was pre-arranged under a Rule 10b5-1 trading plan adopted on February 6, 2026. Following the sale, Henderson directly holds 68,606 shares of Spyre Therapeutics.
Spyre Therapeutics director Henderson sells $2 million in stock By Investing.com
Michael Thomas Henderson, a director at Spyre Therapeutics (NASDAQ: SYRE), sold 20,000 shares of the company's common stock for $2 million on June 22, 2026, at a price of $100 per share. This transaction, executed via a Rule 10b5-1 trading plan, leaves Henderson with 68,606 shares. The sale occurred as the stock trades near its 52-week high, having returned 530% over the past year, though InvestingPro analysis suggests it may be overvalued.
SYRE Maintained by Deutsche Bank -- Price Target Raised to $135
Deutsche Bank has maintained a 'Buy' rating for Spyre Therapeutics (SYRE) and raised its price target from $115 to $135, reflecting optimism about the company's future in treating inflammatory bowel disease and rheumatic diseases. Despite this positive analyst sentiment, Spyre Therapeutics has a low GF Score™ of 33/100, indicating challenges in profitability, and has seen significant insider selling of $17.2 million in the last three months. Investors are advised to consider these mixed signals, balancing growth potential with potential risks.
Deutsche Bank Adjusts Spyre Therapeutics Price Target to $135 From $115, Maintains Buy Rating
Deutsche Bank has increased its price target for Spyre Therapeutics (SYRE) to $135 from $115, while maintaining a Buy rating on the stock. This adjustment reflects the bank's continued positive outlook on the biopharmaceutical company, which specializes in treatments for inflammatory bowel disease and rheumatic diseases. The report was published on June 23, 2026.
SYRE (NASDAQ) Form 144: 20,000 RSUs listed; insider sold 80,000 on 05/08/2026
SYRE (Spyre Therapeutics, Inc.) has filed a Form 144 indicating the proposed resale of 20,000 Restricted Stock Units dated August 28, 2024. The filing also reports previous 10b5-1 sales by Michael Henderson of 80,000 shares on May 8, 2026, totaling $5,952,034. Morgan Stanley Smith Barney LLC is named as the broker involved in these transactions.
SYRE Stock Climbs As Analysts Race To Hike Targets
Spyre Therapeutics Inc. (SYRE) stock surged 14.9% following positive Phase 2 clinical trial results for SPY002 in ulcerative colitis. Multiple analysts, including Deutsche Bank, Wedbush, and BTIG, quickly raised their price targets for SYRE, citing the strong data and a competitor's safety setback. The company's financial health, with substantial cash reserves and no long-term debt, supports its extensive R&D pipeline, which includes six additional Phase 2 readouts scheduled for 2026.
SYRE Stock Climbs As TL1A Data Ignite Analyst Upgrades
Spyre Therapeutics Inc. (SYRE) stock surged following positive clinical trial data from its Phase 2 SKYLINE trial for SPY002 in ulcerative colitis, which met its primary endpoint with strong efficacy and a clean safety profile. This success led to multiple analyst price target upgrades from Wedbush, BTIG, and Deutsche Bank, with some also noting expanded market opportunity after a competitor faced safety issues. The company's strong cash position supports ongoing trials, with further data catalysts expected in 2026.
SYRE Stock Climbs As SPY002 Data Ignite Analyst Upgrades
Spyre Therapeutics Inc. (SYRE) stock has climbed by 13.11% following positive Phase 2 SKYLINE trial data for its therapeutic SPY002 in ulcerative colitis. The strong clinical results and safety profile led analysts from Deutsche Bank, Wedbush, and BTIG to significantly raise their price targets for SYRE. The company also fully enrolled its Phase 2 SKYWAY basket trial for SPY072, broadening its pipeline and setting up multiple 2026 readouts.
Spyre Therapeutics stock hits 52-week high at 95.0 USD
Spyre Therapeutics' stock has reached a new 52-week high of $95.0, reflecting a remarkable 501.77% surge over the past year, though InvestingPro data suggests it may be overvalued. The company recently reported positive phase 2 trial results for SPY002 in ulcerative colitis, raised $463.5 million through a public offering, and completed enrollment for its SKYWAY basket trial. Analysts from Deutsche Bank and Stifel have raised price targets for Spyre, citing strong clinical data and market developments.
Spyre Therapeutics Inc (SYRE) Dividends & Stock Splits: Historical Payouts and Event Timeline
This article provides a historical overview of dividends and stock splits for Spyre Therapeutics Inc (SYRE). It notes that SYRE has not distributed any dividends over the past five years. The article also details several 25-to-1 merger-related stock splits that occurred on September 7, 2023.
Spyre Therapeutics Inc (SYRE) Financial Health: Profitability & Balance Sheet Analysis
This article provides a financial health analysis of Spyre Therapeutics Inc (SYRE), rating its financial score at 5.19, which ranks low in the Biotechnology & Medical Research industry. The report indicates weak financial status and low operational efficiency for the company. Key financial metrics such as cash and cash equivalents, total assets, revenue, and operating profit have not been fully disclosed by the company.
LifeSci Capital Maintains Spyre Therapeutics(SYRE.US) With Buy Rating, Maintains Target Price $103
LifeSci Capital has reiterated its Buy rating for Spyre Therapeutics (SYRE.US) and maintained a target price of $103. This indicates continued confidence from the firm in the pharmaceutical company's future performance.
BTIG Maintains Spyre Therapeutics(SYRE.US) With Buy Rating, Raises Target Price to $112
BTIG has reiterated its Buy rating on Spyre Therapeutics (SYRE.US) and increased its price target to $112. This revision suggests a positive outlook on the company's future performance and valuation. The specific reasons for the raised target and continued Buy rating were not detailed in the provided content.
Spyre reports positive phase 2 trial results for UC drug By Investing.com
Spyre Therapeutics announced positive phase 2 trial results for its ulcerative colitis drug, SPY002, which met its primary endpoint and showed promise in secondary endpoints. Despite being unprofitable, the company has a strong balance sheet and is progressing with other clinical trials, including a public stock offering that raised $463.5 million. Analysts maintain a "Strong Buy" rating for SYRE, with price targets ranging from $78 to $115.
Spyre says bowel disease drug cuts inflammation in mid-stage trial
Spyre Therapeutics announced that its experimental bowel disease drug, SPY002, significantly reduced disease severity in patients with moderate-to-severe ulcerative colitis during a mid-stage trial. The drug met its main goal by cutting inflammation and tissue damage scores by 10.7 points, with secondary results showing clinical remission in 33% of patients and endoscopic improvement in 42%. SPY002, an antibody designed to target the inflammation-driving protein TL1A, was well-tolerated.
Spyre Therapeutics posts positive Phase 2 SKYLINE Part A results for SPY002, RHI -10.7 (p<0.0001)
Spyre Therapeutics announced positive 12-week Part A topline results for SPY002, showing significant improvements in ulcerative colitis patients. SPY002 met its primary endpoint with a 10.7-point reduction in the Robarts Histopathology Index (RHI) and demonstrated high rates of clinical remission and endoscopic improvement. The drug also showed a favorable safety profile, consistent with its class.
